A European Union-supported supercomputing platform assessed the impact of known molecules against the genomic structure of Covid-19 and identified a generic osteoporosis drug's effectiveness, performing in weeks what traditional methods would take years to accomplish.
The EXSCALATE4CoV platform brings together supercomputing centers in Germany, Spain, and Italy, as well as pharmaceutical companies, large research centers, and biological institutes across Europe.
It uses "a unique combination of high-performance computing power and (artificial intelligence), with biological processing," according to the European Commission.
The consortium virtually tested 400,000 molecules with its supercomputers, and tested another 7,000 "in vitro."
The system determined the osteoporosis medication Raloxifene could effectively treat coronavirus patients with mildly symptomatic infection.
View Full Article
Abstracts Copyright © 2020 SmithBucklin, Washington, DC, USA
No entries found